This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks Insiders Love Right Now


One stock that insiders are loading up on here is Biolase (BIOL - Get Report), which develops, manufactures and markets lasers in dentistry and medicine in the U.S. and internationally. Insiders are buying this stock into big time strength, since shares are up sharply by 79% over the last three months.

Biolase has a market cap of $99 million and an enterprise value of $100 million. This stock trades at a reasonable valuation, with a price-to-sales of 1.67 and a price-to-book of 10.74. Its estimated growth rate for this year is -230%, and for next year it's pegged at 69.7%. This is not a cash-rich company, since the total cash position on its balance sheet is $4.15 million and its total debt is $5.53 million.

A beneficial owner just bought 2,035,033 shares, or about $5.23 million worth of stock, at $2.53 to $2.59 per share.

Must Read: 5 Stocks Rising on Unusual Volume

From a technical perspective, BIOL is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending a bit over the last few weeks, with shares moving higher from its low of $2.21 to its recent high of $2.94 a share. During that uptrend, shares of BIOL have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of BIOL within range of triggering a big breakout trade.

If you're bullish on BIOL, then I would look for long-biased trades as long as this stock is trending above its 50-day at $2.49 and then once breaks out above some near-term overhead resistance levels at $2.94 to $3.28 a share and then above $3.55 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 487,464 shares. If that breakout hits soon, then BIOL will set up to re-test or possibly take out its next major overhead resistance levels at $4.11 to $4.50 a share.

2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
BIOL $0.92 -1.92%
LOV $3.77 -0.79%
SFLY $46.25 0.98%
RHI $51.05 0.33%
THRX $9.03 -0.11%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs